Announcements Trials

Browse Landscape

Phase

Phase 3 9 Phase 2 9 Phase 1 4 Phase 2/3 2 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Cancer Recurrent 1

Interventions

pembrolizumab 42 Specimen Handling 38 Magnetic Resonance Spectroscopy 30 Carboplatin 30 Cyclophosphamide 27 Biopsy 25 Nivolumab 23 Dexamethasone 22 fludarabine 21 Gemcitabine 19 Bevacizumab 15 Paclitaxel 14 Temozolomide 13 Pemetrexed 13 Docetaxel 13 Cisplatin 13 atezolizumab 12 Ipilimumab 12 Rituximab 11 venetoclax 10 Prednisone 10 Lenalidomide 9 Injections 9 Fulvestrant 9 lenvatinib 8 X-Rays 8 Vincristine 8 Trastuzumab 8 Oxaliplatin 8 Fluorouracil 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × liposomal doxorubicin × 30 days × Clear all

NCT06843447 2026-05-26

MK-5909-003

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡